Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 01 June 2026, providing investors with the latest insights into its performance and prospects.

At Rs 68.14, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 4.78% on 27 May 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 64.9, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 5% on 26 May 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 61.81, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 4.99% on 25 May 2026, with buyers queuing and no sellers willing to part with shares.

Krebs Biochemicals & Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a tentative stabilisation after a period of significant decline. Despite some improvement in quarterly profitability metrics, the company continues to grapple with steep revenue contraction and persistent losses over the nine-month period, reflecting ongoing challenges in its business operations and market positioning.

Krebs Biochemicals & Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in Active Pharmaceutical Ingredients through fermentation, reported a net loss of ₹2.34 crores in Q4 FY26 (Mar'26), marking the seventh consecutive quarter of losses. With a market capitalisation of just ₹122.00 crores, the company's shares declined 2.15% to ₹53.81 following the results, extending a brutal 27.28% decline over the past year and trading 52.76% below its 52-week high of ₹113.90.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 Feb 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

At Rs 55.58, Krebs Biochemicals & Industries Ltd locked at its lower circuit of 4.02% on 20 May 2026, with sellers lined up but no buyers willing to absorb the supply. The 5% price band limited the daily loss, yet the unfilled sell orders highlight persistent selling pressure and a frozen price.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 Feb 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 10 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and overall outlook.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

At Rs 62.34, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 4.98% on 21 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

At Rs 68.58, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 20% on 6 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 57.15, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 20% on 6 Apr 2026, with buyers queuing and no sellers willing to part with shares.

For the third consecutive session, Krebs Biochemicals & Industries Ltd has seen its share price decline sharply, hitting a fresh 52-week low of Rs 40.92 on 30 Mar 2026. This marks an 11.6% drop over three days, underscoring persistent selling pressure amid broader market weakness.